Skip to main content
SpringerLink
Log in

Infections in cancer patients: some controversial issues

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Despite more than two decades of clinical research into the management of infections in the neutropenic cancer patient, many patients still develop serious morbidity from infection and all too many still die. A number of controversies surround (a) the use of combination versus monotherapy for initial empiric administration; (b) the use of vancomycin as part of the initial regimen; (c) the origin ofStaphylococcus epidermidis infections (i.e., mostly from vascular catheters or mostly from the alimentary canal); (d) the use of acyclovir for herpes simplex prophylaxis during remission induction for acute leukemia patients not undergoing bone marrow transplantation; (e) the use of alimentary canal microbial suppression or reverse isolation in a room with laminar air flow, or both, as infection pevention techniques. Current recommendations and observations include the following. (a) Monotherapy with ceftazidime or imipenem is effective and appropriate for patients with moderate granulocytopenia at limited risk for infection with a resistant organism. Combination therapy is recommended for patients with profound, persistent granulocytopenia who are at high risk for gram-negative bacteremia; such bacteremic patients have a better prognosis with combined-modality therapy. (b) Vancomycin need not be included in the initial regimen although some centers may choose to do so because of the high prevalence of gram-positive bacteremias. (c) Despite the ubiquitous presence of indwelling vascular catheters, mostS. epidermidis infections among neutropenic patients originate from along the alimentary canal. (d) Herpes simplex infection is much more common following standard remission induction chemotherapy than previously recognized. Acyclovir will reduce these infections and concurrently probably reduce the likelihood of resultant bacterial/fungal co-infections and superinfections. (e) Selective microbial suppression is appropriate for patients expected to experience prolonged (more than 2 weeks) or profound (below 100 granulocytes/μl) granulocytopenia. Agents chosen should suppress aerobic but not anaerobic flora (maintain colonization resistance) and need to have an effect on both the oral cavity and esophagus as well as the intestines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Attal M, Schlaifer D, Rubie H, Huguet F, Charlet JP, Bloom E, Lemozy J, Massip P, Pris J, Laurent G (1991) Prevention of gram-positive infections after bone marrow transplantation by systemic vancomycin: a prospective, randomized trial. Clin Oncol 9:865–870

    Google Scholar 

  2. Brandt SJ, Peters WP, Atwater SK, et al (1988) Effect of recombinant human granulocyte-macrophage colonystimulating factor on hematopoietic reconstitution after high-dose chemoterapy and autologous bone marrow transplantation. N Engl J Med 318:869–876

    Google Scholar 

  3. Bustamante CI, Wade JC (1991) Herpes simplex virus infection in the immunocompromised cancer patient. J Clin Oncol 10:1903–1915

    Google Scholar 

  4. Chalfin DB, Blair Holbein ME, Fein AM, Carlon GC (1993) Cost-effectiveness of monoclonal antibodies to gram-negative endotoxin in the treatment of gram-negative sepsis in ICU patients. JAMA 269:249–254

    Google Scholar 

  5. Cushing D, Bustamante C, Devlin A (1991)Aspergillus infection prophylaxis: amphotericin-B nose spray, a double-blind trial (abstract). 31st Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract 737. American Society for Microbiology, Washington, DC

    Google Scholar 

  6. Dekker AW, Rozenberg-Arska M, Verhoef J (1987) Infection prophylaxis in acute leukemia: a comparison of ciprofloxacin with trimethoprim-sulfamethoxazole and colistin. Ann Intern Med 106:7–12

    Google Scholar 

  7. Drouhet E, DuPont B (1987) Evolution of antifungal agents: past present and future. Rev Infect Dis 9 [Suppl 1]:S4–S14

    Google Scholar 

  8. Elting LS, Bodey GP, Keefe BH (1992) Septicemia and shock syndrome due to viridans streptococci: a case-control study of predisposing factors. Clin Infect Dis 14:1201–1207

    Google Scholar 

  9. EORTC International Antimicrobial Therapy Cooperative Group (1978) Three antibiotic regimens in the treatment of infection in febrile granulocytopenic patients with cancer. J Infect Dis 137:14–29

    Google Scholar 

  10. EORTC International Antimicrobial Therapy Cooperative Group (1983) Combination of amikacin and carbenicillin with or without cefazolin as empirical treatment of febrile neutropenic patients. J Clin Oncol 1:597–603

    Google Scholar 

  11. EORTC International Antimicrobial Therapy Cooperative Group (1987) Ceftazidime combined with a short or long course of amikacin for empirical therapy of gram-negative bacteremia in cancer patients with granulocytopenia. N Engl J Med 317:1692–1698

    Google Scholar 

  12. EORTC and National Cancer Institute of Canada (1991) Vancomycin added to empirical combination antibiotic therapy for fever in granulocytopenic patients. J Infect Dis 163:951–958

    Google Scholar 

  13. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (1991) Prevention of bacterial infection in neutropenic patients with hematologic malignancies. A randomized, multicenter trial comparing norfloxacin with ciprofloxacin. Ann Intern Med 115:7–12

    Google Scholar 

  14. Goodman JL, Winston DJ, Greenfield RA, Chandrasekar PH, Fox B, Kaizer H, Shadduck RK, Shea TC, Stiff P, Friedman DJ, et al (1992) A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 326:845–851

    Google Scholar 

  15. Greenman RL, Schein RM, Martin MA, Wenzel RP, MacIntyre NR, Emmanuel G, Chmel H, Kohler RB, McCarthy M, Plouffe J, et al (1991) A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 266:1097–1102

    Google Scholar 

  16. Gribble MJ, Chow AW, Naiman SC, et al (1983) Prospective randomized trial of piperacillin monotherapy versus carboxypenicillin-aminoglycoside combination regimens in the empirical treatment of serious bacterial infections. Antimicrob Agents Chemother 24:388–393

    Google Scholar 

  17. Hann IM, Prentice HG, Corringham R, Blacklock HA, Keaney M, Shannon M, Noone P, Sascoigne E, Fox J, Boesen E, Szawatkowdki M, Hoffbrand AV (1982) Ketoconazole versus nystatin plus amphotericin B for fungal prophylaxis in severely immunocompromised patients. Lancet 1:826–829

    Google Scholar 

  18. Hughes WT, Kuhn S, Chaudhary S, Feldman S, Verzosa M, Aur RJA, Pratt C, George SL (1977) Successful chemoprophylaxis forPneumocystis carinii pneumonitis. N Engl J Med 297:1419–1426

    Google Scholar 

  19. Johnson D, Calia F, Snyder M, Warren J, Schimpff S (1983) Imipenem therapy of Pseudomonas aeruginosa in neutropenic rats. J Antimicrob Chemother 12 [Suppl D]:89–96

    Google Scholar 

  20. Jongh CA de, Joshi JH, Newman KA, Moody MR, Wharton R, Standiford HC, Schimpff SC (1986) Antibiotic synergism and response in gram-negative bacteremia in granulocytopenic cancer patients. Am J Med 80:96–100

    Google Scholar 

  21. Karp JE, Dick JD, Angelopulos C, Charache P, Green L, Burke PJ, Saral R (1986) Empiric use of vancomycin during prolonged treatment-induced granulocytopenia. Randomized, double-blind, placebo-controlled clinical trial in patients with acute leukemia. Am J Med 81:237–242

    Google Scholar 

  22. Karp JE, Merz WG, Hendricksen C, Laughon B, Redden T, Bamberger BJ, Bartlett JG, Saral R, Burke PJ (1987) Oral norfloxacin for prevention of gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 106:1–7

    Google Scholar 

  23. Klastersky J (1986) Concept of empiric theraby with antibiotic combinations. Indications and limits. Am J Med 80 [Suppl 5C]:2–12

    Google Scholar 

  24. Klastersky J, Zinner SH (1982) Synergistic combinations of antibiotics in gram-negative bacillary infections. Rev Infect Dis 4:294–301

    Google Scholar 

  25. Klastersky J, Meunier-Carpentier F, Prevost M (1977) Significance of antimicrobial synergism for the outcome of gram-negative sepsis. Am J Med Sci 273:157–167

    Google Scholar 

  26. Klastersky J, Glauser MP, Schimpff SC, Zinner SH, Gaya H, EORTC International Antimicrobial Therapy Cooperative Group (1986) Prospective randomized comparison of three antibiotic regimens for empirical therapy of suspected bacteremia infection in febrile granulocytopenic patients. Antimicrob Agents Chemother 29:263–270

    Google Scholar 

  27. Liang R, Yung R, Chiu E, Chau PY, Chan TK, Lam WK, Todd D (1990) Ceftazidime versus imipenem-cilastatin as initial monotherapy for febrile neutropenic patients. Antimicrob Agents Chemother 34:1336–1341

    Google Scholar 

  28. Nauseef WM, Maki DG (1981) A study of the value of simple protective isolation in patients with granulocytopenia. N Engl J Med 304:448–453

    Google Scholar 

  29. Ohno R, Tomonaga M, Kobayashi T, Kanamaru A, Shirakawa S, Masaoka T, Omine M, Oh H, Nomura T, Sakai Y, et al (1990) Effect of granulocyte colony-stimulating factor after intensive induction therapy in relapsed or refractory acute leukemia. N Engl J Med 323:871–877

    Google Scholar 

  30. Owens NJ, Nightingale CH, Schweizer RT, Schauer PK, Dekker PT, Quintiliani R (1984) Prophylaxis of oral candidiasis with clotrimazole troches. Arch Intern Med 144:290–293

    Google Scholar 

  31. Perfect JR, Klotman ME, Gilbert CC, Crawford DD, Rosner GL, Wright KA, Peters WP (1992) Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 165:891–897

    Google Scholar 

  32. Pizzo PA, Hathorn J, Hiemenz J, et al (1986) A randomized trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N Engl J Med 315:552–558

    Google Scholar 

  33. Ramphal R, Bolger M, Oblon DJ, Sherertz RJ, Malone JD, Rand KH, Gilliom M, Shands JW Jr, Kramer BS (1992) Vancomycin is not an essential component of the initial empiric treatment regimen for febrile neutropenic patients receiving ceftazidime: a randomized prospective study. Antimicrob Agents Chemother 36:1062–1067

    Google Scholar 

  34. Remington JS, Schimpff SC (1981) Please don't eat the salads. N Engl J Med 304:433–435

    Google Scholar 

  35. Riikonen P (1991) Imipenem compared with ceftazidime plus vancomycin as initial therapy for fever in neutropenic children with cancer. Pediatr Infect Dis J 10:918–923

    Google Scholar 

  36. Rolston KV, Berkey P, Bodey GP, Anaissie EJ, Khardori NM, Joshi JH, Keating MJ, Holmes FA, Cabanillas FF, Elting L (1992) A comparison of imipenem to ceftazidime with or without amikacin as empiric therapy in febrile neutropenic patients. Arch Intern Med 152:283–291

    Google Scholar 

  37. Rousey SR, Russler S, Gottlieb M, et al (1991) Low-dose amphotericin B prophylaxis against invasiveAspergillus infections in allogeneic marrow transplantation. Am J Med 91:484

    Google Scholar 

  38. Rubin M, Hathorn JW, Marshall J, Gress J, Steinberg SM, Pizzo PA (1988) Gram-positive infections and the use of vancomycin in 550 episodes of fever and neutropenia. Ann Intern Med 108:30–35

    Google Scholar 

  39. Sanders JW, Powe NR, Moore RD (1991) Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis. J Infect Dis 164:907–916

    Google Scholar 

  40. Schimpff SC, Satterlee W, Young VM, Serpick A (1971) Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. N Engl J Med 284:1061–1065

    Google Scholar 

  41. Schimpff SC, Young VM, Greene WH, Vermeulen GD, Moody MR, Wiernik PH (1972) Origin of infection in acute nonlymphocytic leukemia. Significance of hospital acquisition of potential pathogens. Ann Intern Med 77:707–714

    Google Scholar 

  42. Schimpff SC, Greene WH, Young VM, Fortner CL, Jepsen L, Cusack N, Block JB, Wiernik PH (1975) Infection prevention in acute nonlymphocytic leukemia. Laminar air flow room reverse isolation with oral, non-absorbable antibiotic prophylaxis. Ann Intern Med 82:351–358

    Google Scholar 

  43. Schimpff SC, Drusano G, Standiford HC (1986) Serum bactericidal test in volunteers—a review. Eur J Clin Microbiol 71:78

    Google Scholar 

  44. Sculier JP, Klastersky J (1984) Significance of serum bactericidal activity in gram negative bacillary bacteremia in patients with and without granulocytopenia. Am J Med 76:429–435

    Google Scholar 

  45. Shenep JL, Hughes WT, Robertson PK, et al (1988) Vancomycin, ticarcillin, and amikacin compared with ticarcillin-clavulanate and amikacin in the empirical treatment of febrile, neutropenic children with cancer. N Engl J Med 319:1053–1058

    Google Scholar 

  46. Tam JY, Blume KG, Prober CG (1992) Prophylactic fluconazole andCandida krusei infections. N Engl J Med 326:891

    Google Scholar 

  47. Tenney JH, Moody MR, Newman KA, Schimpff SC, Wade JC, Costerton JW, Reed WP (1986) Adherent microorganisms on lumenal surfaces of long-term intravenous catheters. Importance ofStaphylococcus epidermidis in patients with cancer. Arch Intern Med 146:1949–1954

    Google Scholar 

  48. Wade JC (1993) Management of infection in patients with acute leukemia. Oncol Clin NA 7:293–315

    Google Scholar 

  49. Wade JC, Schimpff SC, Hargadon MT, Fortner CL, Young VM, Wiernik PH (1981) A comparison of trimethoprim-sulfamethoxazole plus nystatin with gentamicin plus nystatin in the prevention of infections in acute leukemia. N Engl J Med 304:1057–1062

    Google Scholar 

  50. Wade JC, Schimpff SC, Newman KA, Wiernik PH (1982)Staphylococcus epidermidis: an increasing cause of infection in patients with granulocytopenia. Ann Intern Med 97:503–508

    Google Scholar 

  51. Wade JC, Newton B, McLaren C (1982) Intravenous acyclovir to treat mucocutaneous herpes simplex virus infection after marrow transplantation. Ann Intern Med 96:265

    Google Scholar 

  52. Wade JC, Newton B, Flourney N, et al (1984) Oral acyclovir for prevention of herpes simplex reactivation after marrow transplantation. Ann Intern Med 100:823–828

    Google Scholar 

  53. Wade JC, Bustamante C, Devlin A, et al (1987) Inlipenem vs piperacillin plus amikacin empiric therapy for febrile neutropenic patients: a doubleblind trial. 27th Interscience Conference on Antimicrobial Agents and Chemotherapy, abstract 1251. American Society for Microbiology, Washington, DC

    Google Scholar 

  54. Walsh TJ, Lee J, Aoki S, Mechinaud F, Bacher J, Lecciones J, Thomas V, Rubin M, Pizzo PA (1990) Experimental basis for use of fluconazole for preventive or early treatment of disseminated candidiasis in granulocytopenic hosts. Rev Infect Dis 12 [Suppl 3]:S307–S317

    Google Scholar 

  55. Warren HS, Danner RL, Munford (1992) Anti-endotoxin monoclonal antibodies. N Engl J Med 326:1153–1157

    Google Scholar 

  56. Wenzel RP (1992) Anti-endotoxin monoclonal antibodies—a second look. N Engl J Med 326:1151–1152

    Google Scholar 

  57. Wingard JR, Merz WG, Rinaldi MG, Johnson TR, Karp JE, Saral R (1991) Increase inCandida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole. N Engl J Med 325:1274–1277

    Google Scholar 

  58. Winston DJ, Ho WG, Bruckner DA, Champlin RE (1991) Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, ceftazidime plus piperacillin, and imipenem alone. Ann Intern Med 115:849–859

    Google Scholar 

  59. Ziegler EJ, Fisher CJ Jr, Sprung CL, Straube RC, Sadoff JC, Foulke GE, Wortel CH, Fink MP, Dellinger RP, Teng NN, et al (1991) Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 324:429–436

    Google Scholar 

Download references

Author information

Author notes

  1. Daniel A. Scott

    Present address: Department of Medicine, National Naval Medical Center, 8901 Wisconsin Avenue, 20889, Bethesda, MD, USA

Authors and Affiliations

  1. University of Maryland Medical System, 22 South Greene Street, 21201, Baltimore, MD, USA

    Stephen C. Schimpff

  2. Division of Infectious Diseases, Department of Medicine, University of Maryland, School of Medicine, 22 South Greene Street, 21201, Baltimore, MD, USA

    Daniel A. Scott

  3. University of Maryland Cancer Center, University of Maryland, School of Medicine, 22 South Greene Street, 21201, Baltimore, MD, USA

    James C. Wade

Authors
  1. Stephen C. Schimpff
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Daniel A. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. James C. Wade
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

This manuscript is based upon and modified from an update ofComprehensive textbook of oncology to be published by Williams & Wilkins, Baltimore, Md.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schimpff, S.C., Scott, D.A. & Wade, J.C. Infections in cancer patients: some controversial issues. Support Care Cancer 2, 94–104 (1994). https://doi.org/10.1007/BF00572090

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00572090

Key words

Search

Navigation